Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients - Trial NCT06040424
Access comprehensive clinical trial information for NCT06040424 through Pure Global AI's free database. This Phase 3 trial is sponsored by Neutec Ar-Ge San ve Tic A.ล and is currently Recruitment Completed. The study focuses on COPD. Target enrollment is 74 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Neutec Ar-Ge San ve Tic A.ล
Timeline & Enrollment
Phase 3
Sep 28, 2023
Jun 01, 2024
Primary Outcome
FEV1 area under the curve from 0-8 h (FEV1 AUC 0-8 h)
Summary
The goal of this clinical trial is to compare the acute bronchodilator effect of pMDI formed
 Ipratropium / Levosalbutamol 20 mcg / 50 mcg fixed dose combination or pMDI formed Salbutamol
 100 mcg Inhaler and Ipratropium 20 mcg Inhalation Aerosol in combination in stable
 moderate-severe-very severe COPD patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06040424
Non-Device Trial